-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Atsushi Natsume et al.
——Excerpt from the article chapter
【Ref: Natsume A, et al.
Research background
About 70% of low-grade gliomas have isotrate dehydrogenase 1 (IDH1) mutations, resulting in the accumulation of the tumor metabolite D-2-hydroxyglutaric acid (D-2HG), prompting glioma progression, epigenetic disorders, and further clonal amplification
The DS-1001 study for the treatment of relapsed/progressive IDH1-R132 mutant gliomas was a multicenter, open-label, and dose-escalating phase I trial
Research results
The therapeutic dose in the trial did not reach the maximum tolerated doseThe results show that patients with recurrent/progressive IDH1-R132 mutant glioma have good tolerance to DS-1001, can efficiently cross the blood-brain barrier, and have a good effect